Last 12 months
Inside the activity.
6 purchase rows · 11 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 1 | 0 |
| Feb 2026 | 2 | 0 |
| Mar 2026 | 0 | 6 |
| Apr 2026 | 2 | 0 |
| May 2026 | 1 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2009 Filed Mar 3, 2009 02:00 UTC |
MAZZO JAMES VSenior Vice President
|
GrantOption (right to buy) · Derivative | 133,838 | $0.00 Strike: $55.92 | $0.00 |
DisclosureSEC source: 0001104659-09-013603 · a4.xml · derivative · entry 7 MAZZO JAMES V · CIK 0001227297 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,838 Underlying: Common Shares · 133,838 shares Expires 2018-05-29 F7 · security: Fully vested employee stock option received pursuant to the Merger Agreement in exchange for an employee stock option to acquire 326,200 shares of Advanced Medical Optics, Inc. common stock for $22.94 per share. Read SEC document |
| February 26, 2009 Filed Mar 3, 2009 02:00 UTC |
MAZZO JAMES VSenior Vice President
|
GrantOption (right to buy) · Derivative | 75,904 | $0.00 Strike: $93.11 | $0.00 |
DisclosureSEC source: 0001104659-09-013603 · a4.xml · derivative · entry 6 MAZZO JAMES V · CIK 0001227297 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,904 Underlying: Common Shares · 75,904 shares Expires 2015-05-26 F6 · security: Fully vested employee stock option received pursuant to the Merger Agreement in exchange for an employee stock option to acquire 185,000 shares of Advanced Medical Optics, Inc. common stock for $38.20 per share. Read SEC document |
| February 26, 2009 Filed Mar 3, 2009 02:00 UTC |
MAZZO JAMES VSenior Vice President
|
GrantOption (right to buy) · Derivative | 82,058 | $0.00 Strike: $82.19 | $0.00 |
DisclosureSEC source: 0001104659-09-013603 · a4.xml · derivative · entry 5 MAZZO JAMES V · CIK 0001227297 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,058 Underlying: Common Shares · 82,058 shares Expires 2014-05-20 F5 · security: Fully vested employee stock option received pursuant to the Merger Agreement in exchange for an employee stock option to acquire 200,000 shares of Advanced Medical Optics, Inc. common stock for $33.72 per share. Read SEC document |
| February 26, 2009 Filed Mar 3, 2009 02:00 UTC |
MAZZO JAMES VSenior Vice President
|
GrantOption (right to buy) · Derivative | 49,235 | $0.00 Strike: $33.76 | $0.00 |
DisclosureSEC source: 0001104659-09-013603 · a4.xml · derivative · entry 4 MAZZO JAMES V · CIK 0001227297 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,235 Underlying: Common Shares · 49,235 shares Expires 2013-04-29 F4 · security: Fully vested employee stock option received pursuant to the Merger Agreement in exchange for an employee stock option to acquire 120,000 shares of Advanced Medical Optics, Inc. common stock for $13.85 per share. Read SEC document |
| February 26, 2009 Filed Mar 3, 2009 02:00 UTC |
MAZZO JAMES VSenior Vice President
|
GrantOption (right to buy) · Derivative | 98,470 | $0.00 Strike: $21.92 | $0.00 |
DisclosureSEC source: 0001104659-09-013603 · a4.xml · derivative · entry 3 MAZZO JAMES V · CIK 0001227297 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,470 Underlying: Common Shares · 98,470 shares Expires 2012-07-29 F3 · security: Fully vested employee stock option received pursuant to the Agreement and Plan of Merger, dated January 11, 2009, by and among Abbott Laboratories, Rainforest Acquisition Inc. and Advanced Medical Optics, Inc. (the "Merger Agreement") in exchange for an employee stock option to acquire 240,000 shares of Advanced Medical Optics, Inc. common stock for $8.99 per share. Read SEC document |
| February 25, 2009 Filed Feb 28, 2009 00:34 UTC |
TILTON GLENN FDirector
|
PurchaseCommon shares without par value | 2,000 | $53.63 | $107,260.00 |
DisclosureSEC source: 0001104659-09-013203 · a4.xml · nonDerivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,647 Read SEC document |
| February 25, 2009 Filed Feb 28, 2009 00:34 UTC |
LINDER GREG WVice President
|
GrantOption (right to buy) · Derivative | 1,839 | $0.00 Strike: $54.74 | $0.00 |
DisclosureSEC source: 0001104659-09-013204 · a4.xml · derivative · entry 8 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,839 Underlying: Common Shares · 1,839 shares Expires 2014-02-19 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 25, 2009 Filed Feb 28, 2009 00:34 UTC |
LINDER GREG WVice President
|
GrantOption (right to buy) · Derivative | 1,851 | $0.00 Strike: $54.74 | $0.00 |
DisclosureSEC source: 0001104659-09-013204 · a4.xml · derivative · entry 7 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,851 Underlying: Common Shares · 1,851 shares Expires 2013-02-13 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 25, 2009 Filed Feb 28, 2009 00:34 UTC |
LINDER GREG WVice President
|
Exercise / conversionOption (right to buy) · Derivative | 2,454 | $0.00 Strike: $41.03 | $0.00 |
DisclosureSEC source: 0001104659-09-013204 · a4.xml · derivative · entry 6 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 2,454 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 25, 2009 Filed Feb 28, 2009 00:34 UTC |
LINDER GREG WVice President
|
Exercise / conversionOption (right to buy) · Derivative | 3,050 | $0.00 Strike: $33.23 | $0.00 |
DisclosureSEC source: 0001104659-09-013204 · a4.xml · derivative · entry 5 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 3,050 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 25, 2009 Filed Feb 28, 2009 00:34 UTC |
LINDER GREG WVice President
|
Tax withholdingCommon shares without par value | 3,690 | $54.74 | $201,990.60 |
DisclosureSEC source: 0001104659-09-013204 · a4.xml · nonDerivative · entry 3 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,557 Read SEC document |
| February 25, 2009 Filed Feb 28, 2009 00:34 UTC |
LINDER GREG WVice President
|
Exercise / conversionCommon shares without par value | 2,454 | $41.03 | $100,691.79 |
DisclosureSEC source: 0001104659-09-013204 · a4.xml · nonDerivative · entry 2 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,247 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2009 Filed Feb 28, 2009 00:34 UTC |
LINDER GREG WVice President
|
Exercise / conversionCommon shares without par value | 3,050 | $33.23 | $101,355.77 |
DisclosureSEC source: 0001104659-09-013204 · a4.xml · nonDerivative · entry 1 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:00 UTC |
Mason Heather LSenior Vice President
|
GrantOption (right to buy) · Derivative | 38,700 | $0.00 Strike: $54.14 | $0.00 |
DisclosureSEC source: 0001104659-09-011800 · a4.xml · derivative · entry 2 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,700 Underlying: Common Shares · 38,700 shares Expires 2019-02-19 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 12,900 on 02/20/2010, 12,900 on 02/20/2011, and 12,900 on 02/20/2012. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:00 UTC |
Mason Heather LSenior Vice President
|
GrantCommon shares without par value | 27,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-09-011800 · a4.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,377 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:00 UTC |
Hance Robert BSenior Vice President
|
GrantOption (right to buy) · Derivative | 38,700 | $0.00 Strike: $54.14 | $0.00 |
DisclosureSEC source: 0001104659-09-011802 · a4.xml · derivative · entry 3 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,700 Underlying: Common shares · 38,700 shares Expires 2019-02-19 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 12,900 on 02/20/2010, 12,900 on 02/20/2011, and 12,900 on 02/20/2012. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:00 UTC |
Hance Robert BSenior Vice President
|
GrantCommon shares without par value | 27,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-09-011802 · a4.xml · nonDerivative · entry 1 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,284 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:01 UTC |
Warmuth Michael JSenior Vice President
|
GrantOption (right to buy) · Derivative | 38,700 | $0.00 Strike: $54.14 | $0.00 |
DisclosureSEC source: 0001104659-09-011803 · a4.xml · derivative · entry 4 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,700 Underlying: Common shares · 38,700 shares Expires 2019-02-19 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 12,900 on 02/20/2010, 12,900 on 02/20/2011, and 12,900 on 02/20/2012. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:01 UTC |
Warmuth Michael JSenior Vice President
|
GrantCommon shares without par value | 27,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-09-011803 · a4.xml · nonDerivative · entry 1 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,864 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:02 UTC |
Szela Mary TSenior Vice President
|
GrantOption (right to buy) · Derivative | 50,400 | $0.00 Strike: $54.14 | $0.00 |
DisclosureSEC source: 0001104659-09-011809 · a4.xml · derivative · entry 3 Szela Mary T · CIK 0001410289 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,400 Underlying: Common Shares · 50,400 shares Expires 2019-02-19 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 16,800 on 02/20/2010, 16,800 on 02/20/2011, and 16,800 on 02/20/2012. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:02 UTC |
Szela Mary TSenior Vice President
|
GrantCommon shares without par value | 35,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-09-011809 · a4.xml · nonDerivative · entry 1 Szela Mary T · CIK 0001410289 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,955 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:01 UTC |
Landgraf John CSenior Voce President
|
GrantOption (right to buy) · Derivative | 38,700 | $0.00 Strike: $54.14 | $0.00 |
DisclosureSEC source: 0001104659-09-011805 · a4.xml · derivative · entry 5 Landgraf John C · CIK 0001298968 · Senior Voce President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,700 Underlying: Common Shares · 38,700 shares Expires 2019-02-19 F6 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 12,900 on 02/20/2010, 12,900 on 02/20/2011, and 12,900 on 02/20/2012. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:01 UTC |
Landgraf John CSenior Voce President
|
GrantCommon shares without par value | 27,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-09-011805 · a4.xml · nonDerivative · entry 1 Landgraf John C · CIK 0001298968 · Senior Voce President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,608 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:02 UTC |
Bohuon OlivierSenior Vice President
|
GrantOption (right to buy) · Derivative | 50,400 | $0.00 Strike: $54.14 | $0.00 |
DisclosureSEC source: 0001104659-09-011810 · a4.xml · derivative · entry 1 Bohuon Olivier · CIK 0001360215 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,400 Underlying: Common shares · 50,400 shares Expires 2019-02-19 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 16,800 on 2/20/2010, 16,800 on 2/20/11, and 16,800 on 2/20/12. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:01 UTC |
Patton Donald V JRSenior Vice President
|
GrantOption (right to buy) · Derivative | 38,700 | $0.00 Strike: $54.14 | $0.00 |
DisclosureSEC source: 0001104659-09-011806 · a4.xml · derivative · entry 3 Patton Donald V JR · CIK 0001396490 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,700 Underlying: Common Shares · 38,700 shares Expires 2019-02-19 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 12,900 on 02/20/2010, 12,900 on 02/20/2011, and 12,900 on 02/20/2012. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:01 UTC |
Patton Donald V JRSenior Vice President
|
GrantCommon shares without par value | 27,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-09-011806 · a4.xml · nonDerivative · entry 1 Patton Donald V JR · CIK 0001396490 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,226 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:03 UTC |
FREYMAN THOMAS CExecutive Vice President
|
GrantOption (right to buy) · Derivative | 108,200 | $0.00 Strike: $54.14 | $0.00 |
DisclosureSEC source: 0001104659-09-011812 · a4.xml · derivative · entry 6 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,200 Underlying: Common shares · 108,200 shares Expires 2019-02-19 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 36,067 on 2/20/2010, 36,067 on 2/20/2011 and 36,066 on 2/20/2012. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:03 UTC |
FREYMAN THOMAS CExecutive Vice President
|
GrantCommon shares without par value | 76,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-09-011812 · a4.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 390,275 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:03 UTC |
CAPEK JOHN MExecutive Vice President
|
GrantOption (right to buy) · Derivative | 64,900 | $0.00 Strike: $54.14 | $0.00 |
DisclosureSEC source: 0001104659-09-011811 · a4.xml · derivative · entry 2 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,900 Underlying: Common shares · 64,900 shares Expires 2019-02-19 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 21,634 on 02/20/2010, 21,633 on 02/20/2011, and 21,633 on 02/20/2012. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:03 UTC |
CAPEK JOHN MExecutive Vice President
|
GrantCommon shares without par value | 45,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-09-011811 · a4.xml · nonDerivative · entry 1 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,169 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:03 UTC |
LINDER GREG WVice President
|
GrantOption (right to buy) · Derivative | 27,000 | $0.00 Strike: $54.14 | $0.00 |
DisclosureSEC source: 0001104659-09-011814 · a4.xml · derivative · entry 3 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common shares · 27,000 shares Expires 2019-02-19 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 9,000 on 02/20/2010, 9,000 on 02/20/2011, and 9,000 on 02/20/2012. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:03 UTC |
LINDER GREG WVice President
|
GrantCommon shares without par value | 19,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-09-011814 · a4.xml · nonDerivative · entry 1 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,743 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:03 UTC |
ASHLEY RICHARD WExecutive Vice President
|
GrantCommon shares without par value | 47,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-09-011813 · a4.xml · nonDerivative · entry 1 ASHLEY RICHARD W · CIK 0001278570 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,856 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:04 UTC |
Chen Thomas FSenior Vice President
|
GrantOption (right to buy) · Derivative | 38,700 | $0.00 Strike: $54.14 | $0.00 |
DisclosureSEC source: 0001104659-09-011815 · a4.xml · derivative · entry 5 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,700 Underlying: Common shares · 38,700 shares Expires 2019-02-19 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 12,900 on 02/20/2010, 12,900 on 02/20/2011, and 12,900 on 02/20/2012. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:04 UTC |
Chen Thomas FSenior Vice President
|
GrantCommon shares without par value | 27,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-09-011815 · a4.xml · nonDerivative · entry 1 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,232 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:04 UTC |
Michael Edward L.Executive Vice President
|
GrantOption (right to buy) · Derivative | 64,900 | $0.00 Strike: $54.14 | $0.00 |
DisclosureSEC source: 0001104659-09-011816 · a4.xml · derivative · entry 2 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,900 Underlying: Common shares · 64,900 shares Expires 2019-02-19 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 21,634 on 02/20/2010, 21,633 on 02/20/2011, and 21,633 on 02/20/2012. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:04 UTC |
Michael Edward L.Executive Vice President
|
GrantCommon shares without par value | 45,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-09-011816 · a4.xml · nonDerivative · entry 1 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,993 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:04 UTC |
Fussell Stephen RSenior Vice President
|
GrantOption (right to buy) · Derivative | 38,700 | $0.00 Strike: $54.14 | $0.00 |
DisclosureSEC source: 0001104659-09-011817 · a4.xml · derivative · entry 3 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,700 Underlying: Common shares · 38,700 shares Expires 2019-02-19 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 12,900 on 02/20/2010, 12,900 on 02/20/2011, and 12,900 on 02/20/2012. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:04 UTC |
Fussell Stephen RSenior Vice President
|
GrantCommon shares without par value | 27,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-09-011817 · a4.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,752 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. F2 · balance_after: Amount is subject to adjustment pursuant to a domestic relations order. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:05 UTC |
LIEPMANN HOLGER AExecutive Vice President
|
GrantOption (right to buy) · Derivative | 50,400 | $0.00 Strike: $54.14 | $0.00 |
DisclosureSEC source: 0001104659-09-011819 · a4.xml · derivative · entry 5 LIEPMANN HOLGER A · CIK 0001283517 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,400 Underlying: Common shares · 50,400 shares Expires 2019-02-19 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 16,800 on 2/20/2010, 16,800 on 2/20/2011 and 16,800 on 2/20/2012. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:05 UTC |
LIEPMANN HOLGER AExecutive Vice President
|
GrantCommon shares without par value | 35,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-09-011819 · a4.xml · nonDerivative · entry 1 LIEPMANN HOLGER A · CIK 0001283517 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,576 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The awards have a 5 year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:05 UTC |
Tyree James LExecutive Vice President
|
GrantOption (right to buy) · Derivative | 64,900 | $0.00 Strike: $54.14 | $0.00 |
DisclosureSEC source: 0001104659-09-011818 · a4.xml · derivative · entry 3 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,900 Underlying: Common shares · 64,900 shares Expires 2019-02-19 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 21,634 on 02/20/2010, 21,633 on 02/20/2011, and 21,633 on 02/20/2012. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:05 UTC |
Tyree James LExecutive Vice President
|
GrantCommon shares without par value | 45,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-09-011818 · a4.xml · nonDerivative · entry 1 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,443 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:05 UTC |
Schumacher Laura JExecutive Vice President
|
GrantOption (right to buy) · Derivative | 64,900 | $0.00 Strike: $54.14 | $0.00 |
DisclosureSEC source: 0001104659-09-011820 · a4.xml · derivative · entry 2 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,900 Underlying: Common shares · 64,900 shares Expires 2019-02-19 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 21,634 on 02/20/2010, 21,633 on 02/20/2011, and 21,633 on 02/20/2012. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:05 UTC |
Schumacher Laura JExecutive Vice President
|
GrantCommon shares without par value | 45,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-09-011820 · a4.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,109 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:05 UTC |
WHITE MILES DDirector · Chairman and CEO
|
GrantOption (right to buy) · Derivative | 325,000 | $0.00 Strike: $54.14 | $0.00 |
DisclosureSEC source: 0001104659-09-011822 · a4.xml · derivative · entry 6 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,000 Underlying: Common shares · 325,000 shares Expires 2019-02-19 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 108,334 on 2/20/2010, 108,333 on 2/20/2011 and 108,333 on 2/20/2012. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:05 UTC |
WHITE MILES DDirector · Chairman and CEO
|
GrantCommon shares without par value | 92,353 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-09-011822 · a4.xml · nonDerivative · entry 2 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,448,722 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The awards have a 5 year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:05 UTC |
WHITE MILES DDirector · Chairman and CEO
|
GrantCommon shares without par value | 137,647 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-09-011822 · a4.xml · nonDerivative · entry 1 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,356,369 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The awards have a 5 year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 18, 2009 Filed Feb 19, 2009 21:31 UTC |
Hance Robert BSenior Vice President
|
SaleCommon shares without par value | 584 | $54.35 | $31,741.57 |
DisclosureSEC source: 0001104659-09-010782 · a4.xml · nonDerivative · entry 2 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,084 Read SEC document |
| February 18, 2009 Filed Feb 20, 2009 22:39 UTC |
FULLER H LAURANCEDirector
|
Exercise / conversionOption (right to buy) · Derivative | 4,126 | $0.00 Strike: $49.43 | $0.00 |
DisclosureSEC source: 0001104659-09-011219 · a4.xml · derivative · entry 6 FULLER H LAURANCE · CIK 0001187553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 4,126 shares Expires 2009-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.